Compare HYLN & MNPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HYLN | MNPR |
|---|---|---|
| Founded | 2018 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Construction/Ag Equipment/Trucks | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 328.1M | 368.9M |
| IPO Year | 2019 | 2019 |
| Metric | HYLN | MNPR |
|---|---|---|
| Price | $5.78 | $62.74 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 11 |
| Target Price | $5.00 | ★ $107.00 |
| AVG Volume (30 Days) | ★ 2.6M | 164.9K |
| Earning Date | 05-12-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 54.99 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $3,475,000.00 | N/A |
| Revenue This Year | $197.93 | N/A |
| Revenue Next Year | $301.97 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 130.28 | N/A |
| 52 Week Low | $1.14 | $28.40 |
| 52 Week High | $4.84 | $105.00 |
| Indicator | HYLN | MNPR |
|---|---|---|
| Relative Strength Index (RSI) | 86.80 | 56.98 |
| Support Level | $1.77 | $51.71 |
| Resistance Level | N/A | $67.90 |
| Average True Range (ATR) | 0.54 | 5.65 |
| MACD | 0.25 | 0.27 |
| Stochastic Oscillator | 91.75 | 68.24 |
Hyliion Holdings Corp designs and develops power generators for stationary and mobile applications and provides R&D service. It provides solutions that enable clean, flexible, and affordable electricity production. The company focuses on delivering distributed power generators that can operate on various fuel sources to future-proof against an ever-changing energy economy. In addition to stationary power solutions, it focuses on mobile applications, including vehicles and marine technologies. Its products and services include: KARNO Power Modules which is a modular, fully enclosed, fuel-agnostic and fully integrated power generating solution.
Monopar Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients. The company's pipeline consists of Validive for the prevention of chemoradiotherapy-induced severe oral mucositis in oropharyngeal cancer patients, camsirubicinfor the treatmentof soft tissue sarcoma, a late-stage preclinical antibody, MNPR-101, for cancers and severe COVID-19 and an early-stage camsirubicin analog, MNPR-202, for various cancers.